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Improving patient quality of life and functional status is an important aim of research and
development in ILDs with a progressive phenotype. Measures of patients’ perceptions and patient-
reported outcomes will be required to understand our interventions. http://ow.ly/neQu30mCS89
Cite this article as: Swigris JJ, Brown KK, Abdulqawi R, et al. Patients’ perceptions and patient-reported
outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180075 [https://doi.
org/10.1183/16000617.0075-2018].
ABSTRACT The effects of interstitial lung disease (ILD) create a significant burden on patients,
unsettling almost every domain of their lives, disrupting their physical and emotional well-being and
impairing their quality of life (QoL). Because many ILDs are incurable, and there are limited reliably-
effective, life-prolonging treatment options available, the focus of many therapeutic interventions has been
on improving or maintaining how patients with ILD feel and function, and by extension, their QoL. Such
patient-centred outcomes are best assessed by patients themselves through tools that capture their
perceptions, which inherently incorporate their values and judgements. These patient-reported outcome
measures (PROs) can be used to assess an array of constructs affected by a disease or the interventions
implemented to treat it. Here, we review the impact of ILD that may present with a progressive-fibrosing
phenotype on patients’ lives and examine how PROs have been used to measure that impact and the
effectiveness of therapeutic interventions.
Introduction
Some patients with interstitial lung diseases (ILDs) develop progressive fibrosis. A terminology recently
used to describe patients with fibrosing ILDs that may present a progressive phenotype is
progressive-fibrosing ILD (PF-ILD) [1]. PF-ILD is potentially life-shortening and unquestionably affects
how patients feel and function in their daily lives [1]. Activity-limiting dyspnoea, nagging cough and
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debilitating fatigue impair patients’ physical and emotional well-being and quality of life (QoL).
Experience with idiopathic pulmonary fibrosis (IPF) shows that, with disease progression, patients lose
their independence and are forced to rely on their caregivers to assist them with daily activities and
self-care [2].
The broad goals of therapy for any condition are to improve how patients feel or function, or how long
they survive. The way to best understand how a condition affects patients (i.e. to learn the symptoms it
causes and how it makes them feel physically, what impairments it imposes on their functioning, how it
impacts their emotional well-being, its effects on their QoL and which of these effects matter to them) is
to ask the experts: the patients themselves [3]. Once patients’ perceptions are known, the path to
developing or identifying tools to assess them becomes clearer. Although measuring abstract constructs
(like QoL) can be challenging, it can be done. The methods involve capturing patients’ perceptions via
surveys or questionnaires [3]. By gathering responses directly from patients, these patient-reported
outcome measures (PROs) inherently include patients’ values and judgements [3].
Although lung function measures are useful, they yield incomplete information on how patients with
PF-ILD are feeling and functioning [3]. In comparison, PROs produce more comprehensive, personalised
information on the outcomes most meaningful to patients [3]. PROs may paint the clearest picture of the
influence a disease has on a patient’s life, and they can be used to determine whether (and how)
therapeutic interventions induce changes important to patients in the target population.
Here, we review the published data on how PF-ILD affects patients’ lives, how PROs have been used to
capture those effects and what additional work is required to improve how we assess outcomes meaningful
to patients with PF-ILD. PROs have been used in studies relating to IPF, but there have been few specific
studies of PROs in other PF-ILDs [3]. Where appropriate, we have assessed the evidence in IPF as a
surrogate for other PF-ILDs.
Impact on patients’ lives
Patients’ perspectives on diagnosis
Unfortunately, the emotional toll paid by patients diagnosed with PF-ILD typically begins long before the
diagnosis is confirmed. Published data reveal, after coming to medical attention, it takes patients with IPF
(on average) longer than a year and multiple visits to physicians to be diagnosed [4].
Having to wait a long time before a diagnosis is made and living that time without a name to explain the
cause of their symptoms (leaving patients unaware of what they are up against), generates anxiety for
patients who feel they are unable to prepare themselves for what living with the disease entails [5, 6].
COLLARD et al. [7] administered surveys to 1448 patients with IPF, nearly two-thirds of whom (63.5%)
reported being ill-informed about disease management. Patients have also expressed frustrations about a
lack of patient-friendly, readily-available, easily-accessible information on IPF at the time of their
diagnosis. Similarly, all-comers with connective tissue disease related-ILD, or cohorts of patients with
rheumatoid arthritis- or systemic sclerosis-related (SSc)-ILD have expressed confusion around their
diagnoses and recognised a need for improved patient–doctor communication [8, 9]. In IPF, the past
couple of years have witnessed progress toward answering the call for more educational resources. Such
tools are critical to helping patients better prepare themselves for what can be an uncertain future living
with the disease. Part of this preparation involves learning healthy coping strategies to deal with negative
thoughts and feelings. The involvement of practitioners, including experienced nurses or behavioural
health experts, who are trained to help patients navigate the emotional effects of living with a progressive,
chronic illness assures adequate support in selected cases.
Day-to-day life
Cough and activity-limiting dyspnoea have immense impact on the everyday lives of patients with IPF and
other ILDs [2, 10–12]. Cough can affect sleep, willingness to participate in social activities [9] and thus,
physical and emotional well-being. Fatigue can be equally debilitating and lead to decreased social
participation, physical deconditioning, low mood and isolation [2, 10, 12, 13].
In patients with PF-ILD, dyspnoea limits physical activity in many ways [8, 9]. Some patients avoid certain
activities altogether, because the dyspnoea those activities induce is overwhelming; many patients describe
having to slow down or stop and rest (perhaps multiple times) to complete an activity. For patients with
IPF, this is frustrating and compounds the burden of facing an uncertain future that will probably include
worsening health, the need for supplemental oxygen and shortened survival [10].
As the disease progresses, patients’ declining physical functioning limits their ability to look after
themselves, forcing them to rely on others (most often a spouse) for help [2]. In the latter stages of IPF,
performing basic tasks, such as showering or simple household chores, becomes a struggle [2, 10].
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Besides posing a substantial threat to patients’ physical well-being, PF-ILD can negatively impact patients’
mental well-being. Patients may suffer from bouts of anxiety and/or depression and develop feelings of
grief and anger [9, 12]. Living with, and coming to terms with a terminal illness, is remarkably difficult
[6]. Patients with IPF struggle to cope with the loss of independence and grieve the loss of the lives they
once enjoyed [2, 14]. Patients can also feel disconnected with family, as they are unable to participate in
family life and care for others [9, 10].
Patients’ expectations of treatment
An ideal treatment would prolong survival, improve QoL and functional status, and reduce the frequency
and severity of symptoms [10]. Currently, there are no “cures” for PF-ILD. There are no approved
treatment options for PF-ILDs, although corticosteroids and immunosuppressive therapies are sometimes
used. While the antifibrotic medications, recently approved to treat IPF (pirfenidone and nintedanib), may
slow disease progression, neither was associated with consistent, beneficial effects on symptoms or QoL
across phase II and III trials, and neither are approved for the treatment of other PF-ILDs. Specific
treatments for fibrosing ILDs that may present a progressive phenotype are covered in more detail by
RICHELDI et al. [15].
Oxygen therapy is commonly given to alleviate dyspnoea in IPF [14]. This treatment relies on access to
oxygen, and requires patients to carry, push or pull tanks and to wear a cannula or have a catheter to
breathe in the oxygen. Having to use oxygen can leave patients housebound [10]. The idea of being
connected to a machine or tank to receive oxygen is unpleasant, and IPF patients would welcome more
convenient oxygen delivery systems that would enable them to be more physically mobile and to travel [10].
The authors recognise that the treatments themselves (taking antifibrotics and/or using supplemental
oxygen) can be sources of stress and anxiety for patients. Practitioners aware of this possibility, and able to
deal with it if it occurs, are likely to help patients remain adherent to therapeutic interventions.
PROs
A PRO is defined as “any report of the status of a patient’s health condition that comes directly from the
patient, without interpretation of the patient’s response by a clinician or anyone else” [16]. PROs aim to
ascertain patient’s perspectives on any number of things, including overall health status, symptoms or QoL
[3]. Typically, information is gathered via questionnaires or surveys [3]. PROs can be symptom- or
disease-specific or generic [14].
How a disease specifically influences patients in their daily lives cannot be fully captured through other
measures of disease severity or activity, like tests of pulmonary physiology and chest imaging [3]. Although
weak to moderately strong correlations between PRO scores and those tests support the validity of PROs,
each is at least peripherally associated with how patients feel and function, the richness of the patient’s
perspective on living with a disease can only be captured by gathering their perceptions.
PROs used in clinical trials
The vast majority of ILD-related clinical trials have focused on IPF and generally used lung function and/
or mortality as primary end-points. PROs could easily be used in clinical trials to evaluate symptoms, the
effectiveness of a drug and progression of disease [16]. However, few interventional trials have been
focused on patient well-being [11, 17] and, when used in these studies, PROs have mainly been regarded
as lower-tier end-points [3, 11, 12, 14].
PROs that have been used in studies include dyspnoea indices, cough questionnaires, health status
instruments, health-related QoL (HRQoL) measures, depression or anxiety questionnaires and sleep
surveys [3]. St. George’s Respiratory Questionnaire (SGRQ) has been used in IPF and other PF-ILD trials
to assess respiratory health status [11, 18]. Dyspnoea-specific PROs have also been used to evaluate
treatment response [11, 19]. The Medical Outcome Study short-form 36 (SF-36) and the EuroQoL-5D are
questionnaires that have been used to assess health status and HRQoL [11, 20, 21]. Anxiety and depression
have been quantified using the Hospital Anxiety and Depression Scale and the Generalised Anxiety
Disorder Questionnaire – 7 item [22]. An overview of the most widely used PROs in IPF are summarised
in tables 1 and 2 [14].
ILD-specific PROs
To date, the PROs most commonly used in IPF trials were originally intended for other uses, including
assessing outcomes in patients with other respiratory diseases [37, 38]. PROs developed for chronic
obstructive pulmonary disease (COPD), including the SGRQ and COPD assessment tests, have been
studied in patients with IPF [12, 14]. Despite some items lacking face validity for IPF, the SGRQ appears
to perform reasonably well (particularly its Activities domain) as a measure of health status and symptom
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severity in patients with IPF. A modified version of the SGRQ has been developed particularly for patients
with IPF [12]. The reliability and validity of this PRO is comparable with the original SGRQ as
demonstrated by certain psychometric parameters (e.g. internal consistency) and correlation with relevant
disease severity measures. However, longitudinal response data are needed to further assess its
performance in IPF [14].
A questionnaire specifically developed for ILDs is the King’s Brief ILD (K-BILD) health status
questionnaire [14, 25]. The K-BILD requires longitudinal evaluation in PF-ILD [11].
TABLE 1 Summary of the most widely used disease-specific patient-reported outcome measures (PROs) in IPF
PRO Description Number of items Domains assessed Disadvantages Advantages
SGRQ [23] Disease-specific instrument
designed to measure impact
on overall health, daily life
and perceived well-being in
patients with obstructive
airways disease
50 Symptoms component;
activities that cause or are
limited by breathlessness;
impact components (social
functioning, psychological
disturbances resulting
from airways disease)
Originally developed
for COPD and
asthma; lengthy,
difficult
questionnaire
Used in many IPF
clinical trials
SGRQ-I IPF-specific version of
original SGRQ
34 Symptoms component;
activities that cause or are
limited by breathlessness;
impact components (social
functioning, psychological
disturbances resulting
from airways disease)
Limited experience Questions more
relevant for IPF than
SGRQ
CAT [24] Patient-completed
questionnaire assessing
globally the impact of COPD
on health status
8 (one question
assessing impact
on sleep)
Unidimensional, assesses
cough, sputum, dyspnoea
and chest tightness
Clinically important
minimal difference
remains to be
rigorously studied
Simple and quick
K-BILD [25] Brief, valid, self-completed
health status measure for
ILD
15 Three health domains:
psychological,
breathlessness and
activities, and chest
symptoms
Limited experience
in clinical trials,
although
increasingly used
Developed to assess
patients with ILD
ATAQ-IPF [3] Multidimensional
questionnaire designed for
IPF
74 13 domains including
dyspnoea, cough, fatigue,
independence and
emotional health
Covers the patient
identified domains of
interest
L-IPF [26] Modified variant of the
ATAQ-IPF, consisting of two
modules: symptoms and
impacts
Severity and impact of
dyspnoea, cough and
energy; global impact
Not available yet Adapted with
feedback from
patients
IPF-PROM Concise questionnaire to
assess QoL in IPF; currently
in development
Not available yet Not available yet Developed with
patients and
caregivers
PESaM Generic and disease-specific
module; evaluates patients’
expectations, experiences
and satisfaction with
disease-modifying drugs
Not validated yet;
responsiveness
unknown
Developed together
with IPF patients
IPF-PREM Questionnaire to assess
experiences with care
delivery
Not available yet Measures
experiences of
patients
IPF: idiopathic pulmonary fibrosis; SGRQ: St. George’s Respiratory Questionnaire; SGRQ-I: SGRQ for patients with IPF; CAT: COPD Assessment
Test; K-BILD: King’s Brief Interstitial Lung Disease; ATAQ-IPF: A Tool to Assess Quality of Life in IPF; L-IPF: living with IPF; IPF-PROM:
IPF-Patient reported outcome measure; PESaM: Patient Experiences and Satisfaction with Medications; IPF-PREM: IPF-patient reported
experience measure; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; QoL: quality of life. Modified from [14].
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TABLE 2 Summary of the most widely used domain-specific patient-reported outcome measures (PROs) in IPF
PRO Description Number of
items
Domains assessed Disadvantages Advantages
Dyspnoea
SOBQ [27] Self-administered rating of dyspnoea
associated with activities of daily living
24 21 items assess severity of
shortness of breath during
specific activities of daily life;
three additional items ask about
limitations due to: shortness of
breath, fear of harm from
overexertion and fear of
shortness of breath
mMRC [28] Assesses the severity of functional
dyspnoea using a graded system (grade
0 (not troubled with breathlessness) to
grade 4 (too breathless to leave the
house))
1 Quick, easy tool for use in
daily practice; relates to
disease progression
BDI-TDI [29] BDI: interviewer-administered rating of
severity of dyspnoea at a single state, it
provides a multidimensional
measurement of dyspnoea based on
three components that evoke dyspnoea
in activities of daily living, in
symptomatic individuals
TDI: measures changes in dyspnoea
severity from the baseline established
by the BDI
24 BDI: functional impairment,
magnitude of task, magnitude
of effort; recall: during the past
2 weeks
TDI: change in functional
impairment, change in
magnitude of task, change in
magnitude of effort
Few specific instructions included
in the instrument
Measures both baseline
and change over time
Borg Scale Measures level of dyspnoea scored on a
scale from 0 to 10
Only measures dyspnoea during
exertion, does not measure
dyspnoea over time
Useful during 6-min walk
test in daily practice
FACIT-D [30, 31] Evaluates dyspnoea severity FACIT-D short
form: 10 items
FACIT-D long
form: 33 items
Asking patients to evaluate their
shortness of breath across a
range of functional activities
completed over a week
Disease specific measure
Cough
LCQ [32] Patient-reported questionnaire evaluating
the impact of a cough on QoL
19 Three domains: physical,
psychological and social
Limited experience in IPF
Its specific nature may limit its
usefulness when a broader
assessment of QoL is desired,
patients may need to complete
multiple questionnaires if more
comprehensive assessment is
required
Reliable, responsive to
changes, easy to
complete
CQLQ Validated measure of cough-specific QoL 28 Six domains Good validity for total score in
IPF, but not for all domains
Comprehensive;
responsive outcome
measure
Continued
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TABLE 2 Continued
PRO Description Number of
items
Domains assessed Disadvantages Advantages
Fatigue
FAS [33] General fatigue questionnaire 10 Questions reflect physical and
mental fatigue
Quick and easy to
complete
FACIT-FS [34] Questionnaire to assess fatigue in patients
with cancer
13 Not specific for ILD Reliable and valid scale
Anxiety
HADS [35] Measures anxiety and depression in a
general medical population
14 Comprises seven questions for
anxiety and seven for
depression
Should not be used as a
diagnostic test; not originally
developed in ILD
Reliable screening tool for
anxiety and depression;
simple and easy to use
GAD-7 [36] Measure of GAD 7 Not specific to ILD Valid and efficient tool for
screening for GAD and
assessing its severity in
clinical practice and
research
IPF: idiopathic pulmonary fibrosis; SOBQ: Shortness of Breath Questionnaire (University of California San Diego); mMRC: modified Medical Research Council; BDI-TDI: Baseline Dyspnoea
Index-Transition Dyspnoea Index; FACIT-D: Functional Assessment of Chronic Illness Therapy Dyspnoea; LCQ: Leicester Cough Questionnaire; CQLQ: cough-specific quality-of-life
questionnaire; FAS: Fatigue Assessment Scale; FACIT-FS: Functional Assessment of Chronic Illness Therapy Fatigue Scale; HADS: Hospital Anxiety and Depression Scale; GAD-7:
Generalised Anxiety Disorder-7; QoL: quality of life; ILD: interstitial lung disease. Modified from [14].
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Symptom-specific PROs that have been used to assess outcomes in patients with ILDs are summarised in
table 2. These include the University of California San Diego Shortness of Breath Questionnaire, the
modified Medical Research Council (mMRC) scale, the Mahler Baseline and Transition Dyspnoea indexes
and the Borg scale [11, 14]. Recently, the Functional Assessment of Chronic Illness Therapy-Dyspnoea has
been shown to possess validity for assessing dyspnoea in patients with SSc [39]. The mMRC score has been
shown to predict survival in patients with IPF [40], but has not been verified for use in patients with
SSc-ILD [11].
Although cough is a common symptom of many ILDs, questionnaires have not been developed to assess
cough severity or impacts specifically for patients with PF-ILD [14]. In the authors’ opinion,
characterisation of this potentially debilitating symptom would be beneficial. The Leicester Cough
Questionnaire is currently considered suitable for use in clinical trials (particularly in IPF) [11, 14], but
the utility of the Cough QoL Questionnaire in other ILDs that may present a progressive-fibrosing
phenotype remains to be elucidated [11].
While fatigue is an important symptom, to date, no specific fatigue questionnaires for IPF exist. As with
cough, such a tool may or may not be needed. The Fatigue Assessment Scale, originally developed for
sarcoidosis, has been used [14]. The Functional Assessment of Chronic Illness Therapy Fatigue Scale has
been validated for use in SSc-ILD [11].
An IPF-specific PRO is currently being developed with the input of a multidisciplinary team of patients
and carers [41]. An IPF-specific QoL instrument, A Tool to Assess Quality of Life in IPF, and its modified
variant, the living with IPF questionnaire [14] have been developed and are in the late stages of US Food
and Drug Administration qualification.
Barriers to PRO use in clinical studies
Relevance of existing PROs for assessing HRQoL
Using disease-specific and validated PROs in the clinical arena could improve quality of care by alerting
practitioners to effects of disease that may otherwise go unrecognised. In the research arena, PROs allow
measurement of disease-specific effects not captured by other outcomes. Widely used PROs fail to address
certain aspects deemed important by patients [11, 12]. For example, in IPF, patients generally experience a
non-productive cough; however, some patients report a productive “hacking cough”, which is not captured
in current PROs [10, 13]. Some language in the SGRQ, such as “attack” or “attacks of the chest”, do not
resonate with IPF patients, as they feel that this does not correctly describe their disease experience [13]. A
“sometimes” response option would be useful to capture IPF patients’ perceptions on some true/false
items on the SGRQ more accurately [13]. A category missing from HRQoL questionnaires is one that
includes items addressing the impact of supplemental oxygen on QoL [13]. Because many patients with
PF-ILDs will need supplemental oxygen, it is imperative that the impact of this treatment on patient’s lives
is captured [13].
For any PRO to be useful as a research tool, its basic psychometric properties must be confirmed to fall
within the acceptable ranges. For PROs that have been used in IPF research, some of these properties
remain to be determined [13]. For a PRO to be used as an end-point in longitudinal research, data to
support its longitudinal validity must be generated. For tools currently under development, such data are
accruing [13].
Optimising PROs for research and clinical use
A reliable measure to assess patient experiences with medical interventions would be helpful. Because
each patient is an individual, the effects of a disease or its treatment may vary from person to person,
depending on several factors. Investigators in the Netherlands have developed the patient experiences and
satisfaction with medications measure [42] to assess tolerance and perceived effectiveness of pirfenidone
in IPF.
Together with patients, RUSSELL et al. [41] are developing an IPF-specific, patient-reported experience
measure (PREM). The PREM aims to assess patient experiences with healthcare, with the hope that it
could be used to improve the quality of care provided to patients. Additional studies of these measures are
eagerly awaited.
In clinic, PROs could be a useful metric to assess disease status and patient well-being. However, in a busy
clinic, PRO administration may not be practical. Shorter PROs may be required, but they may not yield
data with the richness or depth that clinicians desire. Having patients complete PROs delivered
electronically the day or week prior to a clinic visit could be considered. The assessment of HRQoL by
smartphone applications is currently being investigated. Capturing PRO response data with this modality
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could help facilitate clinical assessment, patient–physician communication and monitoring individual
HRQoL over the course of treatment [43, 44].
Conclusion
PROs could help clinicians focus on matters of high concern to patients and help investigators determine
whether therapies influence the outcomes of the greatest importance to them. Additional research is
needed to determine the performance characteristics of existing PROs in patients with ILDs that may
present a progressive-fibrosing phenotype.
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